+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

“Global Rheumatoid Arthritis market set to grow to $47bn by 2024” says new Visiongain report

16 December 2018
Pharma

Visiongain has launched a new pharma report Global Rheumatoid Arthritis Drugs Market Report : Biologics, Non-Biologics, NSAIDs, sDMARDs and Others.

Demand for RA drugs is on the rise, particularly in developing countries. The TNF inhibitors, which have dominated the market so successfully, are now coming to the end of their patents, opening the way for new biologics and biosimilars to compete for their share of the market. Following the launch of Xeljanz there are other oral DMARDs in development which could potentially undermine the role of the biologics. Changes in the next few years will be critical in determining the future treatment for RA.

The lead analyst of the report commented "one factor driving growth in this market is the discovery of new molecules that are involved in the disease process, hence, new strategies for treating the disease. Molecules such as TNFα, interleukin 6, interleukin 1, and janus kinase have all enabled the development of new treatments to target these molecules.

There are also several restraints on the RA drugs market which discourage the introduction of new drugs. One of these is the increasing pressure from governments to reduce the size of healthcare budgets and restrict the price of drugs. There are also drives to encourage physicians to prescribe generics and biosimilars rather than branded products, and to increase the percentage of patients who receive such products from year to year."

Leading companies featured in the report include AbbVie, Amgen, AstraZeneca, BMS, Eli Lilly, Johnson & Johnson, Merck & Co, Novartis, Pfizer, Roche, Sanofi, UCB

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Drug Delivery Technologies Market Report 2024-2034

The global Drug Delivery Technologies market is estimated at US$1,729.6 billion in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period 2024-2034.

23 April 2024

Read

Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

18 April 2024

Read

Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

17 April 2024

Read

Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

12 April 2024

Read